Top NYC, NY Health Tech Companies With Best Stability & Growth (635)

Strategic Partnerships: Long‑running collaborations with Boehringer Ingelheim and Otsuka, plus a 2025 strategic investment from Dassault Systèmes/Medidata, reinforce scale and credibility. Evidence suggests these alliances provide development resources, commercialization pathways, and platform reach.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD; CT‑132 for preventive episodic migraine) and the acquisition of AspyreRx expand the portfolio across psychiatry, neurology, and cardiometabolic care. Late‑stage CT‑155 Phase 3 success and Breakthrough Device status add pipeline depth.

Investor Backing & Capital Strength: Recent fundraising and M&A momentum amid a consolidating market indicate access to capital and financial resilience. This capital base supports evidence generation, scaling, and entry into new categories.

Strong Market Position & Advantage: Headway is often characterized as a leader among insurance‑enabled mental‑health provider networks, with national footprint and a large active provider network cited. The notion that “largest” depends on metric still acknowledges an advantage on provider‑network scale and insurer breadth.

Market Expansion: Operations are described as live across all 50 states and D.C., with stated rollouts into Medicare Advantage and Medicaid broadening reach beyond commercial plans. Independent trade press is referenced for the national expansion and payer‑specific launches.

Investor Backing & Capital Strength: Late‑stage raises, including a 2023 Series C and a reported ~$2.3B valuation linked to 2024 fundraising, indicate strong investor conviction and resources to scale. Coverage presents these financings as signals that investors view the company as a category leader.

Strong Market Position & Advantage: Coverage consistently characterizes Zocdoc as a U.S. category leader for consumer discovery of in‑network clinicians with instant booking across 200+ specialties. The brand is widely recognized and operates at national scale connecting millions of patients to real‑time, in‑network care.

Strategic Partnerships: Recent collaborations with health plans and health systems—such as Blue Shield of California integration and CommonSpirit pilots—demonstrate institutional traction and extended distribution beyond solo practices. These partnerships signal durable adoption and broadened channels for patient scheduling.

Profitability: Leadership states the company returned to profitability by 2023 and delivered profitable growth through 2024–2025. Earlier turnarounds to EBITDA profitability pre‑pandemic reinforce financial durability.

Investor Backing & Capital Strength: Feedback suggests Camber benefits from substantial venture support, including a recent Series B led by a top-tier investor. This capitalization is described as enabling product build‑out and go‑to‑market execution.

Market Expansion: Feedback suggests the company is broadening its footprint across many states and moving beyond behavioral health into adjacent care settings. Public materials cite multi‑state coverage and plans to enter home health, long‑term care, and substance use care.

Innovation-Driven Growth: Feedback suggests AI‑driven billing workflows and automation underpin Camber’s reported throughput and collection improvements. This technology focus appears well‑suited to complex payer rules in targeted niches.

Strong Market Position & Advantage: Broad adoption across large pharma and recognition as a leader in physics‑based discovery software indicate a durable competitive edge, reinforced by flagship tools like Glide and FEP+ with peer‑reviewed validation. Penetration across all top global pharma and sticky, long‑tenure accounts suggest standard‑tool status in discovery teams.

Strong Revenue Growth: Recent results show higher software revenue and total revenue growth in 2025, with guidance pointing to continued expansion in software ACV in 2026. Management frames software as the scaled growth engine while hosted deployments rise.

Strategic Partnerships: Large, multi‑year collaborations with major pharmas and long‑running technical work with NVIDIA support pipeline upside and platform performance. Deal structures with upfronts, milestones, and potential royalties diversify growth levers.

Investor Backing & Capital Strength: Recent funding rounds led by Goldman Sachs Alternatives and IVP are cited, supporting expansion of predictive AI, integrations, and skilled nursing investment. This capital base suggests the company is well-resourced to pursue growth plans.

Strategic Partnerships: Public updates highlight expanding integrations with major senior‑living EHRs (e.g., ALIS, Yardi, ECP, with PointClickCare and August Health timelines). These connections aim to position the platform alongside, rather than replacing, incumbent systems.

Market Expansion: Company communications report deployments across hundreds of communities in many states and portfolio‑wide rollouts with multi‑site operators. Stated plans include deeper moves into skilled nursing settings.

Strong Market Position & Advantage: Industry tallies continue to place Pfizer among the global top tier by pharmaceutical revenue and scale, with company guidance keeping it one of the largest drugmakers by sales. Leadership by platforms and global footprint is reinforced by sustained positions in major rankings and markets.

Diversified Revenue Streams: The portfolio spans vaccines (e.g., Prevnar/Prevenar, Abrysvo), cardiovascular/rare disease (Eliquis alliance, Vyndaqel), oncology (legacy brands plus Seagen assets), and anti-infectives, providing multiple contributors as COVID revenues normalize. Product mix in 2025 highlighted several sizable non-COVID franchises supporting the base business.

Future-Ready Strategy: Management emphasizes oncology expansion via the Seagen acquisition, a broad late-stage pipeline with many pivotal starts slated for 2026, and cost/operations programs to fund R&D. These actions are positioned to drive a late‑decade growth reacceleration as near-term headwinds abate.

Strong Revenue Growth: Repeated Inc. 5000 recognition over multiple consecutive years signals sustained multi‑year top‑line expansion. Company announcements highlight ongoing product launches and acquisitions consistent with continued scaling.

Diversified Customer Base: The company serves employers, K‑12 districts, ABA practices, payors, and users across many countries, indicating breadth across end markets. Presence with large enterprises and major school systems suggests reduced dependency on any single buyer segment.

Innovation-Driven Growth: The platform leverages a uniquely large autism outcomes dataset and AI to power predictive analytics and clinical decision support. Industry awards for healthcare analytics and AI-focused executive appointments underscore innovation as a core growth driver.

Investor Backing & Capital Strength: Recent large financing and a reported unicorn valuation position the company among the best-capitalized players in insurer-covered telenutrition. Multiple outlets and investors are cited as supporting expansion of its platform, clinical network, and payer relationships.

Strong Market Position & Advantage: The company is characterized as a leader in insurance-covered, RD-led tele-nutrition with nationwide reach and broad in-network coverage. Sources highlight a very large RD workforce and payer alignment that lowers patient friction to access care.

Strategic Partnerships: Partnerships with major health plans, health systems, and adjacent services (e.g., pharma access points and medically tailored meals) extend distribution and program depth. These relationships reinforce enterprise credibility and enable growth across chronic-condition use cases.

Strategic Partnerships: Cleveland Clinic expanded systemwide use of AKASA’s coding tools and later added CDI, and AKASA has a collaboration with Cerner/Oracle Health. These relationships indicate enterprise validation and distribution fit within major EHR ecosystems.

Product Line Growth: New GenAI offerings such as Authorization Advisor, Medical Coding, and a CDI Optimizer were launched across 2024–2025. This signals expansion from back‑end automation into mid‑cycle accuracy and documentation capabilities.

Investor Backing & Capital Strength: The company secured a sizable funding round in 2024 and reports significant total capital raised. This capitalization supports continued product development and go‑to‑market scaling.

Investor Backing & Capital Strength: Public trackers and company materials indicate roughly mid-teens millions in recent funding and notable backers, providing meaningful early-stage capital to scale. Job postings and profiles align this capital with expansion plans.

Strong Hiring & Retention: Company profiles show an 11–50 employee band and multiple recent role postings across functions, signaling active team build-out. Visible recruiting for founding and leadership roles suggests momentum in organizational growth.

Innovation-Driven Growth: The offering is positioned as an AI-native advocate combining agentic AI with human support, with a live consumer app and ongoing iteration. Rebranding from Medbill AI to Granted and frequent product updates point to innovation-led execution.

Innovation-Driven Growth: Independent coverage highlights AI, robotics, 3D printing, and real-time dentist–lab collaboration across Dandy’s Utah and Texas facilities and software stack. This end-to-end digital model is described as uncommon in the broader lab landscape and positions the company as a tech-forward operator.

Product Line Growth: Multiple launches—AI Scan Review, Live Design Review, the Dandy Vision intraoral scanner, Dandy Cart, digital dentures, and DSO analytics tools—indicate expanding offerings across hardware, software, and lab services. This cadence suggests increasing breadth from scan capture to manufacturing and practice analytics.

Strategic Partnerships: Sign-ups from practices at more than 80 DSOs and named relationships with multi-location groups are cited alongside frequent presence at major dental meetings. These connections deepen access to scaled customer channels and reinforce commercial momentum.

Strong Market Position & Advantage: Industry analyses and company disclosures depict GoodRx as the leading U.S. prescription discount and price-comparison platform by scale, usage, and brand visibility. This position is reinforced by broad pharmacy acceptance and sustained revenue at national scale.

Diversified Revenue Streams: Management is expanding beyond coupons into manufacturer programs, subscriptions, telehealth, and integrated point‑of‑sale savings. Rapid growth in manufacturer solutions has begun to counterbalance softness in legacy transactions.

Strategic Partnerships: Collaborations with major drug manufacturers and PBM/pharmacy programs (e.g., insulin affordability and biosimilar cash‑price offerings, integrated savings at checkout) extend distribution and deepen ecosystem integration. These relationships enhance consumer access and relevance with pharma and retail stakeholders.

Strong Market Position & Advantage: Analyst assessments from Everest Group, IDC MarketScape, and Forrester frequently place ZS in the Leader tier across life-sciences AI/analytics, digital services, HCP engagement, and R&D ITO. Feedback suggests this convergence of recent, scoped evaluations signals durable competitive standing in its core niches.

Market Expansion: ZS cites 13,000+ to 15,000+ professionals across 35–40+ offices and opened a new 50,000‑sq‑ft Hyderabad site, indicating expanded global delivery capacity. Capability-led acquisitions (e.g., Digital Additive; Torrent Consulting) further broaden geographic and service reach.

Innovation-Driven Growth: The firm launched a dedicated Platform & Products unit and is scaling ZAIDYN and Max.AI to embed AI and productized capabilities into client programs. Feedback suggests these moves position ZS for growth beyond services via AI-enabled, repeatable solutions.

Strong Market Position & Advantage: Feedback suggests Vetcove is the leading supplier‑agnostic purchasing hub in U.S. veterinary procurement with broad clinic adoption across settings. Legal/industry descriptions as a de facto aggregator and manufacturer inclusion as a primary purchasing channel reinforce this advantage.

Market Expansion: Feedback suggests reported clinic usage has grown from earlier counts into the 23,000+ range, pointing to steady penetration gains. Added integrations and visibility within daily clinic workflows indicate continued expansion momentum.

Strategic Partnerships: Feedback suggests deep ecosystem embedding via integrations with major practice systems and appearances alongside large distributors on partner pages. Manufacturer and association programs listing Vetcove as a purchasing channel further underscore strong partner alignment.

Investor Backing & Capital Strength: Funding milestones and valuation step-ups indicate strong capital access, including a 2024 Series D establishing unicorn status and a 2025 $250M round reportedly above $2.2B. These signals align with late‑stage category leaders and provide runway for product and market expansion.

Strong Market Position & Advantage: Industry references cite a large multifamily footprint (e.g., ~1.5M units across ~200 property managers) and characterize the firm as a leader in AI for housing. Visible presence across major operators and listings ecosystems supports the view of front‑of‑pack positioning in its core vertical.

Strategic Partnerships: Distribution and ecosystem ties—such as Zillow’s AI Assist being powered by the company and public recognition by OpenAI as a trusted partner—signal channel leverage and technical credibility. Named relationships with large operators further strengthen go‑to‑market reach.

Investor Backing & Capital Strength: Raised a $372M Series D in June 2024 led by Andreessen Horowitz with Sanofi participating, placing it among larger techbio financings and enabling aggressive asset licensing. Total funding above $600M and strategic capital from Sanofi signal strong financial support for scaling.

Strategic Partnerships: Entered a first-of-its-kind three-way collaboration with Sanofi and OpenAI to build AI software for drug development, indicating differentiated platform recognition. Additional marquee transactions with Sanofi (e.g., gusacitinib license) reinforce high-signal partner engagement.

Product Line Growth: Multiple sizable deals expanded and activated the portfolio, including licensing gusacitinib to Sanofi and acquiring a TYK2 inhibitor via Bleecker Bio and an oral miR-124 activator via Kenmare Bio. Public coverage cites several active clinical programs, including one in Phase 3, consistent with ongoing pipeline buildout.

Investor Backing & Capital Strength: Public reporting indicates a $150M Series D in March 2026 at a roughly $3B valuation with participation from top-tier investors, signaling substantial capital availability to fund expansion. Coverage across multiple industry outlets corroborates strong investor demand for the company’s infrastructure-led approach.

Strategic Partnerships: Integrations span 125+ insurers with explicit expansion into employer and health‑system channels (e.g., bridging EAP sessions to ongoing in‑network care and partnerships like Circle Medical), indicating multi‑channel distribution strength. These footholds are presented as key markers of category leadership in enablement-focused behavioral health.

Strong Revenue Growth: Reports tied to the 2026 round cite approximately $1B in annual revenue alongside 7 million visits in 2025 and a national provider network, suggesting rapid scaling in monetized utilization. Broad payer coverage and growing enterprise channels reinforce momentum in top‑line expansion.

Market Expansion: Public materials highlight growth from roughly 2,500+ to 5,500–6,000+ research sites across 50+ countries and an increase to 25+ sponsors on the platform. Feedback suggests the marketplace is scaling on both the supply (sites) and demand (sponsors) sides.

Strategic Partnerships: Named collaborations with AbbVie, Sanofi, and Moderna, plus integrations with RealTime‑Devana and CRIO, demonstrate blue‑chip adoption and expanding ecosystem reach. Feedback suggests repeated use on consequential trials and data‑sharing ties are strengthening commercial durability.

Innovation-Driven Growth: Recent launches such as AI Site Selection and AI patient pre‑screening target bottlenecks in planning, site selection, and enrollment. External recognition (e.g., Fast Company’s Most Innovative Companies with adoption more than doubling in 2023) signals momentum behind product innovation.

Investor Backing & Capital Strength: Recent financing, including a sizable Series B in 2025, indicates strong investor confidence and runway to scale go‑to‑market and product. Reports note the raise followed observed traction rather than active fundraising, reinforcing capital strength.

Innovation-Driven Growth: A steady cadence of AI‑native releases—such as claims analytics and a platform redesign—shows momentum in automation and decision support for employees and HR. The platform’s AI assistant focus aligns with efforts to deflect HR tickets and clarify coverage.

Strategic Partnerships: Expanding routes to market via alliances and channels (e.g., PEOs/brokers and program integrations) broaden access without relying solely on direct sales. These relationships suggest increasing reach among mid‑market employers and ecosystem buyers.